SCHEMBL5655895

SCHEMBL5655895

CCOc1ccccc1NC(=O)OCCCN1CCN(c2cc(C)ccc2C)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
LMNA P02545 3/20 0.57
ALDH1A1 P00352 2/20 0.57
USP2 O75604 1/20 0.57
TSHR P16473 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
MAPT P10636 4/20 0.52
POLB P06746 2/20 0.51
MAPK1 P28482 1/20 0.51
TP53 P04637 3/20 0.50
HTR1A P08908 2/20 0.49
HTR2A P28223 2/20 0.49
DRD2 P14416 4/20 0.49
DRD4 P21917 3/20 0.49
DRD3 P35462 3/20 0.49
ADRA1A P35348 2/20 0.49
HTR7 P34969 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5657076 0.91 ADRA1D (0.53) KMT2ALMNAUSP2MAPTHTR2A
SCHEMBL5666061 0.90 ADRA1A (0.57) MEN1KMT2ANPSR1MAPTPOLB
SCHEMBL5655836 0.87 GAA (0.50) KMT2ASMN1; SMN2LMNAALDH1A1TSHR
SCHEMBL5656021 0.86 MAPT (0.58) MEN1KMT2ASMN1; SMN2LMNAALDH1A1
SCHEMBL5655907 0.85 ADRA1D (0.53) LMNAHTR1AHTR2ADRD2DRD4
SCHEMBL5654887 0.85 ADRA1A (0.66) MEN1KMT2AALDH1A1MAPK1HTR1A
SCHEMBL5666368 0.85 KMT2A (0.51) KMT2ALMNAALDH1A1USP2TSHR
SCHEMBL5656119 0.85 PKM (0.61) MEN1KMT2ALMNAALDH1A1TSHR
SCHEMBL5656354 0.84 DRD2 (0.53) MEN1KMT2ALMNAALDH1A1USP2
SCHEMBL5657183 0.82 DRD2 (0.55) POLBHTR1AHTR2ADRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof CEREP (FR) 2004-03-25 US disclosed
EP-1362041-A1 ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF Cerep (FR) 2003-11-19 EP disclosed
WO-2002068399-A1 ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF CEREP (FR) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof HTR4, HTR5A, HTR3C MEN1 3474/4885KMT2A 2124/4885SMN1; SMN2 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.